Patients with a certain type of lung cancer — stage II to IIIB non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation — saw better results when treated with the ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment "Choosing the first treatment for EGFR-mutated NSCLC is ...

"The survival curve tells a clear story. RYBREVANT plus LAZCLUZE helps patients live longer, and the benefit keeps growing over time," said trial investigator Professor Nicolas Girard*, M.D., Ph.D., ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...